Key facts, as of
As of October 22, 2026, Pfizer Inc. (PFE) trades at $30.42, up 23.1% over the past year. It is at the top of its 52-week range ($23.62 to $30.44). It is 50.7% below its all-time high of $61.71, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +39.8%, against +312.9% for the S&P 500 (SPY). It sits 14.1% above its 200-day average of $26.66, the usual sign of a long-term uptrend. Its 30-day volatility is 18.4% annualized, which we rate medium risk. It has a trailing P/E of 40.0 and a dividend yield of 5.76%. Pfizer Inc. (PFE) has confirmed its next earnings report for November 3, 2026, before the market opens (date from Yahoo Finance, listed on our November 2026 earnings calendar).
Cite: Portfolio Terminal, "Pfizer Inc. (PFE) stock analysis", 2026-10-22. https://portfolio-terminal.com/analyse/pfe
Where it trades today
trading 100% of the way up its 52-week range
How the price has moved
How far it is from its record
Pfizer Inc. (PFE) is 50.7% below its all-time high of $61.71, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +39.8%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- PFE trades at 40.0x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- PFE carries a beta of 0.28, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- PFE is in a bullish short-term regime and only 0.1% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- PFE is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in PFE.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- The view would need revisiting if peers such as UNH, JNJ, ABBV start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for PFE come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, ABBV.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for PFE. Last refresh: Oct 22, 2026, 10:09 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, ABBV.
What Pfizer Inc. does
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for…
Employees
75,000
Industry
Drug Manufacturers - General
Headquarters
New York, United States
What analysts expect
PFE carries a buy consensus from 26 analysts, with an average price target of $29.26 versus $30.42 today (-3.8%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
PFE generated $63.70B in trailing revenue (2.6% year over year), with a 6.8% net margin, and $12.49B of free cash flow, against $51.78B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $62.58B | $46.51B | $17.41B | $7.77B | $1.37 | $9.07B |
| 2024 | $63.63B | $45.78B | $14.94B | $8.03B | $1.42 | $9.84B |
| 2023 | $59.55B | $34.60B | $4.42B | $2.12B | $0.38 | $4.79B |
| 2022 | $101.17B | $66.83B | $38.12B | $31.37B | $5.59 | $26.03B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
PFE is in 15 of the 54 ETFs we track. It weighs most in XLV: 2.63% of the fund, holding #10 of 62.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
PFE beside the healthcare names it is usually measured against.
What the chart is saying
Trading at its high for the year, with no resistance overhead.
uptrend- Price is 7.8% above its 50-day average and 14.1% above its 200-day.
- The 50-day crossed above the 200-day on 2026-09-11 (a “golden cross”).
- RSI at 72 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $28.97 (-4.8%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is PFE a good investment in 2026?
Pfizer Inc. trades at a P/E ratio of 40.0, with medium volatility (18.4% annualized). Recent momentum is positive.
What is the risk level of PFE?
Based on 30-day volatility of 18.4%, PFE has MEDIUM risk. Beta of 0.28 indicates lower sensitivity to market movements than average.
Does PFE pay dividends?
Yes, Pfizer Inc. has a dividend yield of 5.76%.
How far is PFE from its all-time high?
Pfizer Inc. is 50.7% below its all-time high of $61.71, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +39.8%, against +312.9% for the S&P 500 (SPY).
When does Pfizer Inc. report earnings?
Pfizer Inc. (PFE) reports its next quarterly earnings on Tuesday, November 3, 2026, before the market opens. The company has confirmed the date; it comes from Yahoo Finance's earnings data and is listed on the Portfolio Terminal November 2026 earnings calendar. For that quarter, the analysts' consensus Yahoo Finance reports is earnings of $0.73 per share.
Which ETFs hold PFE?
15 of the 54 popular ETFs we track hold Pfizer Inc.. The largest weights: XLV (2.63%), VYM (0.69%), VTV (0.62%), SPY (0.26%) and CSPX (0.26%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is PFE?
0.25%, as of September 30, 2026: PFE is holding #73 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $2.47 in Pfizer Inc..
What is the analyst price target for PFE?
The average analyst price target for Pfizer Inc. (PFE) is $29.26 based on 26 analyst estimates, about 3.8% below the current price of $30.42. The published range runs from $25.00 to $36.00.
How much revenue does PFE generate?
Pfizer Inc. reported $63.70B in trailing twelve-month revenue. Revenue growth is running at 2.6% year over year. Net margin sits at 6.8%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare PFE with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.